Want to see JP:4967 full AI Analyst Report?
Top Page
Kobayashi Pharmaceutical Co
(4967)
Select Model
Select Model
Rating:61Neutral
Price Target:
¥5,862.00
▲(7.11% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily supported by a very strong, low-debt balance sheet and improved 2025 cash generation, which underpin financial resilience. Offsetting this are sharply weaker profitability versus prior years and a very high P/E valuation, while technical indicators are mostly neutral and do not materially strengthen the outlook.
Positive Factors
Conservative Balance Sheet
Extremely low debt and sizable equity (~¥205–213B vs total assets) provide durable financial resilience, preserving flexibility to fund operations, absorb shocks, and pursue selective investments or buybacks without relying on leverage, supporting stability over the next months.
Negative Factors
Earnings Decline
A steep multi-year drop in net income indicates persistent margin pressure or cost/headwind issues that erode the company’s ability to generate returns. Continued weaker profitability reduces reinvestment capacity and risks further declines in ROE and shareholder distributions.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Extremely low debt and sizable equity (~¥205–213B vs total assets) provide durable financial resilience, preserving flexibility to fund operations, absorb shocks, and pursue selective investments or buybacks without relying on leverage, supporting stability over the next months.
Read all positive factors
Kobayashi Pharmaceutical Co (4967) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥405.89B
Dividend Yield1.92%
Average Volume (3M)221.72K
Price to Earnings (P/E)249.7
Beta (1Y)0.30
Revenue Growth3.71%
EPS Growth-86.23%
CountryJP
Employees3,731
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)41.28
Shares Outstanding78,050,000
10 Day Avg. Volume218,190
30 Day Avg. Volume221,720
Financial Highlights & Ratios
PEG Ratio-1.73
Price to Book (P/B)1.91
Price to Sales (P/S)2.43
P/FCF Ratio32.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)140.07
Revenue Forecast (FY)¥172.65B
Kobayashi Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The co...
How the Company Makes Money
Kobayashi Pharmaceutical primarily makes money by selling branded, high-turnover consumer products across OTC health and household categories. Its core revenue model is product sales (recognized when products are shipped/sold through distribution ...
Kobayashi Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
92
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 166.80B | 165.74B | 165.60B | 173.46B | 166.26B | 155.25B |
| Gross Profit | 85.10B | 84.71B | 87.60B | 96.38B | 92.33B | 88.77B |
| EBITDA | 12.37B | 12.52B | 21.96B | 33.65B | 33.33B | 32.49B |
| Net Income | 3.07B | 3.66B | 10.07B | 20.34B | 20.02B | 19.71B |
Balance Sheet | ||||||
| Total Assets | 254.86B | 275.33B | 265.37B | 267.47B | 255.83B | 252.55B |
| Cash, Cash Equivalents and Short-Term Investments | 65.03B | 70.61B | 65.75B | 79.84B | 104.53B | 109.05B |
| Total Debt | 727.00M | 678.00M | 846.00M | 987.00M | 792.00M | 630.00M |
| Total Liabilities | 45.94B | 64.32B | 51.89B | 62.66B | 57.93B | 56.95B |
| Stockholders Equity | 208.92B | 211.00B | 213.47B | 204.82B | 197.90B | 195.60B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 12.34B | -14.81B | 5.60B | 17.17B | 18.76B |
| Operating Cash Flow | 0.00 | 25.59B | 11.25B | 18.36B | 31.91B | 22.42B |
| Investing Cash Flow | 0.00 | -154.00M | -18.41B | -19.58B | -14.31B | 7.99B |
| Financing Cash Flow | 0.00 | -7.92B | -7.77B | -19.46B | -20.76B | -10.38B |
Kobayashi Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥487.84B | 17.72 | 8.90% | 1.74% | 6.21% | 37.97% | |
74 Outperform | ¥3.31T | 24.59 | 12.16% | 2.36% | 6.19% | 21.69% | |
72 Outperform | ¥664.56B | 19.35 | 12.11% | 1.82% | 9.67% | -2.92% | |
68 Neutral | ¥337.74B | 24.46 | 3.71% | 2.42% | 3.22% | 357.77% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥405.89B | 249.66 | 1.46% | 1.92% | 3.71% | -86.23% | |
58 Neutral | ¥1.45T | -70.35 | ― | 1.64% | 4.96% | -1485.59% |
* Consumer Defensive Sector Average
JP:4967
Kobayashi Pharmaceutical Co
5,473.00
145.19
2.73%
JP:4452
Kao
3,654.00
292.85
8.71%
JP:4922
Kose
5,920.00
232.28
4.08%
JP:4912
Lion
1,797.50
202.86
12.72%
JP:4527
Rohto Pharmaceutical Co
2,862.50
406.71
16.56%
JP:4911
Shiseido Company,Limited
3,619.00
1,104.95
43.95%
Kobayashi Pharmaceutical Co Corporate Events
Kobayashi Pharma to Divest Loss-Making China Unit in Strategic Shift
Aug 6, 2026
Kobayashi Pharmaceutical has decided to transfer all its equity interest in Jiangsu Kobayashi Pharmaceutical, a loss-making Chinese manufacturing subsidiary, to Venturepharma Pharmaceutical (Xiamen), resulting in Jiangsu Kobayashi ceasing to be an...
Kobayashi Pharmaceutical’s Profit Slumps Despite Higher Sales, Dividend Outlook Intact
Aug 6, 2026
Kobayashi Pharmaceutical reported a modest 2.5% rise in net sales to ¥70.7 billion for the six months ended June 30, 2026, but saw operating profit plunge 67.5% and profit attributable to owners of parent fall 64.1%. Despite weaker earnings, ...
Kobayashi Pharmaceutical Posts Profit Slump but Holds 2026 Outlook and Lifts Dividend
May 8, 2026
Kobayashi Pharmaceutical reported consolidated net sales of ¥33.67 billion for the three months ended March 31, 2026, up 3.2% year on year, while operating profit fell 46.7% to ¥1.35 billion and profit attributable to owners of parent de...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.